APP2021: Professor David Hunter on how pharmacists can facilitate more positive OA management outcomes

Osteoarthritis (OA) is a leading cause of disability that affects more than 3 million Australians.

At APP 2021, Professor David Hunter, Florance and Cope Chair of Rheumatology, Professor of Medicine, the University of Sydney spoke to Miranda Deakin about the opportunities for pharmacists to facilitate more positive OA management outcomes for patients.  


This video is proudly supported by GSK Consumer Healthcare

GSK Consumer Healthcare is the world’s largest consumer healthcare company, with a broad portfolio of products spanning pain relief, specialist oral health, skin health, nutrition and digestion. Australians know GSK Consumer Healthcare best for trusted brands like Panadol, Voltaren, Sensodyne, Polident, Advil and Centrum which have become household names.

Trade marks are owned by or licensed to the GSK group of companies. ©2020 GSK group of companies or its licensor.


Previous Is the revolution coming?
Next List of pharmacy case locations grows

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.

No Comment

Leave a reply